drugset / Trial / NCT07661498

Indomethacin for Biliary ERCP Patients

NCT07661498

Phase 4 Not yet recruiting 860 enrolled University of California, San Francisco
RandomizedParallel-groupSingle-blindPrevention

Summary

This study is a randomized clinical trial evaluating the efficacy of rectal indomethacin in preventing post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis in patients undergoing biliary ERCP who have a history of prior biliary sphincterotomy. While rectal indomethacin has demonstrated benefits in preventing post-ERCP pancreatitis in high-risk patients, its utility in this specific patient subgroup remains unclear. This trial aims to determine whether prophylactic administration of indomethacin offers a measurable benefit over no intervention in this lower-risk population. Eligible patients will be identified prior to their scheduled biliary ERCP and screened for inclusion criteria. Following informed consent, participants will be randomized to receive either rectal indomethacin or no indomethacin prior to the procedure.

Timeline

Start
2026-07
Primary completion
2031-07
Completion
2031-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Indomethacin Small molecule 100 mg

Indications